Full text is available at the source.
Abstract
A decade-long analysis of prescription trends found differences in the use of SGLT2 inhibitors and GLP-1 receptor agonists among adults with type 2 diabetes.
- Prescription patterns for SGLT2 inhibitors and GLP-1 receptor agonists may show significant variations over ten years.
- Real-world data from Epic Cosmos provides insights into the treatment landscape for adults with type 2 diabetes.
- Differences in prescribing trends could reflect changes in clinical guidelines or patient preferences.
Simplified